



CP 1164/13  
VPI/SW/002 CIP2 FWC DIV2 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

JUL 31 2002

TECH CENTER 1600/2900

Examiner : Cybille Delacroix-Muirheid  
Group : 1614  
Applicants : Paul R. Sleath et al.  
Application No. : 09/670,106 Confirmation No. 5809  
Filed : September 26, 2000  
For : INTERLEUKIN 1 $\beta$  PROTEASE AND  
INTERLEUKIN 1 $\beta$  PROTEASE INHIBITORS

New York, New York  
July 23, 2002

Hon. Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

TRANSMITTAL LETTER FOR  
INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith is an Information Disclosure Statement in the above-identified application. This Statement is submitted more than three months from the application filing date and after the mailing date of the first Office Action on the merits, but before the mailing date of either a final action under 37 C.F.R. § 1.113 or a notice of allowance under 37 C.F.R. § 1.311.

In accordance with 37 C.F.R. § 1.97, submission of this Statement requires a fee as set forth in 37 C.F.R. § 1.17(p). A check in the amount of \$180.00 is enclosed herewith.

The Director is hereby authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this response is enclosed.

RECEIVED

JUL 3 1 2002

Respectfully submitted,

TECH CENTER 1600/2900



James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Min Wang (Reg. No. 51,303)

Kimberley A. Gavin (Reg. No. P-51,723)

Agents for Applicants

c/o FISH & NEAVE (Customer No. 1473)

1251 Avenue of the Americas

New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. BOX 2327  
ARLINGTON, VA 22202 on

July 23, 2002

Lillian Garcia

  
Signature of Person Signing



VPI /SW/002 CIP2 FWC DIV2 CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Cybille Delacroix-Muirheid  
Group : 1614  
Applicants : Paul R. Sleath et al.  
Application No. : 09/670,106 Confirmation No. 5809  
Filed : September 26, 2000  
For : INTERLEUKIN 1 $\beta$  PROTEASE AND  
INTERLEUKIN 1 $\beta$  PROTEASE INHIBITORS

RECEIVED

JUL 31 2002

TECH CENTER 1600/2900

New York, New York  
July 23, 2002

Hon. Commissioner for Patents  
P.O. Box 2327  
Arlington, VA 22202

STATEMENT UNDER 37 C.F.R. §§ 1.97 AND 1.56

Sir:

Pursuant to 37 C.F.R. § 1.56 and 1.97, applicants, through their  
representatives, make of record the following documents:\*

---

\* For the convenience of the Examiner, a completed Form PTO-1449 listing these documents is attached hereto in duplicate. The above-identified application is a continuation of U.S. application No. 09/039,609, filed March 16, 1998, now U.S. Patent 6,136,787; which is a division of U.S. application No. 08/440,179, filed May 12, 1995, now U.S. Patent 5,756,465; which is a division of U.S. application No. 08/203,716, filed February 28, 1994, now U.S. patent 5,416,013; which is a continuation of U.S. application No. 07/750,644, filed August 30, 1991, now abandoned; which is a continuation-in-part of U.S. application No. 07/505,298, filed April 4, 1990, and U.S. application No. 07/656,759, filed February 13, 1991, both now abandoned.

### UNITED STATES PATENTS

<u>Patent No.</u>	<u>Issue Date</u>
4,636,492	January 13, 1987
4,644,055	February 17, 1987
4,652,552	March 24, 1987
4,808,523	February 28, 1989
5,104,853	April 14, 1992
5,225,354	July 6, 1993
5,304,481	April 19, 1994
5,756,465	May 26, 1998

### FOREIGN PATENT PUBLICATIONS

<u>Publication No.</u>	<u>Publication Date</u>
EP 0 272 671	June 24, 1988
EP 0 533 350	March 24, 1993
WO91/15577	October 17, 1991
WO93/05071	March 18, 1993

### REFERENCES

- Beuscher et al. IL-1 beta is secreted by activated murine macrophages as biologically inactive precursor. *J. Immunol.* **144**, 2179 (1990).
- Black et al. Generation of biologically active interleukin-1 $\beta$  by proteolytic cleavage of the inactive precursor. *J. Biol. Chem.* **263**, 9437 (1988).
- Black et al. A pre-aspartate-specific protease from human leukocytes that cleaves pro-interleukin 1 $\beta$ . *J. Biol. Chem.* **264**, 5323 (1989).
- Black et al. Activation of interleukin-1 $\beta$  by a co-induced protease. *FEBS Letts.* **247**, 386 (1989).
- Black et al. Identification of a protease that processes interleukin-1 $\beta$ . In *Molecular and Cellular Biology of Cytokines*. (J. Oppenheim, M. Powanda, M. Kluger, C. Dinarello, Eds.) pp. 69–74, Wiley-Liss, New York, NY (1990).
- Black et al. Purification and molecular cloning of the IL-1 $\beta$  processing enzyme. *J. Cell. Biochem. Supp.* **15G**, CH 201 (1991).
- Black et al. The proteolytic activation of interleukin-1b. In *Progress in Inflammation Research and Therapy*. (N. Ackerman, R. Bonney, A. Welton, Eds.) pp. 85–89 Birkhauser Verlag, Basel (1990).
- CAPLUS DN 116 50949, Rosenthal et al. *J. Clin. Invest.* **88**, 1467 (Abstract) (1991).

- CAPLUS DN 118: 208112, Thornberry et al. *Nature* **35**, 768 (Abstract) (1992).
- Casano et al. The structure and complete nucleotide sequence of the murine gene encoding interleukin-1 $\beta$  converting enzyme (ICE). *Genomics* **20**, 474 (1994).
- Cerretti et al. Molecular cloning of the IL-1 $\beta$  processing enzyme. *J. Cell. Biol. Supp.* **F15**, P506 (1991).
- Cerretti et al. Molecular cloning of the IL-1 $\beta$  processing enzyme. *Cytokine* p. 137 (1991).
- Cheremisinoff et al. (eds). *Biotechnology Applications and Research*, Technomics Publ. Co, Inc. pp. 21, 541-557 (1985).
- Dower et al. The interleukin-1 system: Receptors, ligands and signals. *Chem. Immunol.* **51**, 33 (1992).
- Dreyer et al. Inhibition of human immunodeficiency virus 1 protease in vitro: rational design of substrate analogue inhibitors. *Proc. Natl. Acad. Sci. USA* **86**, 9752 (1989).
- Hazuda et al. The kinetics of interleukin 1 secretion from activated monocytes. *J. Biol. Chem.* **263**, 8473 (1988).
- Howard et al. IL-1-converting enzyme requires aspartic acid residues for processing of the IL-1 $\beta$  precursor at two distinct sites and does not cleave 31-kDa IL-1 $\alpha$ . *J. Immunol.* **147**, 2964 (1991).
- Kitada et al. New peptide models for studying racemization. *Chem. Pharm. Bull.* **26**, 585 (1978).
- Knittel et al. Stimulation of insulin secretion from pancreatic islets by the cholecystokinin-tetrapeptide analogs Trp-Pro-Asp-Phe-NH<sub>2</sub> and Trp-Pro-Asp-Phe(4'-NO<sub>2</sub>)-NH<sub>2</sub>. *Pept. Res.* **3**, 224 (1990).
- Koga et al. Comparative study on specifics of rat cathepsin L and papain: amino acid differences as substrate binding sites are involved in their specificities. *J. Biochem.* **108**, 976 (1990).
- Kostura et al. Identification of a monocyte specific pre-interleukin 1 $\beta$  convertase activity. *Proc. Natl. Acad. Sci. USA* **86**, 5227 (1989).
- Lee et al. Generation of cDNA probes directed by amino acid sequence: Cloning of urate oxidase. *Science* **239**, 1288 (1988).
- Malek et al. Amino acid sequence of an invertebrate FBP aldolase (from *Drosophila melanogaster*). *Biochem. Biophys. Res. Comm.* **126**, 195 (1985).
- March et al. Cloning, sequence and expression of two distinct human interleukin-1 complementary DNAs. *Nature* **315**, 641 (1985).

McQuade et al. A synthetic HIV-1 protease inhibitor with antiviral activity arrests HIV-like particle maturation. *Science* **247**, 454 (1990).

Mosley et al. Determination of the minimum polypeptide lengths of the functionally active sites of human interleukins 1 alpha and 1 beta. *Proc. Natl. Acad. Sci. USA* **84**, 4572 (1987).

Rasnick. Synthesis of peptide fluoromethyl ketones and the inhibition of human cathepsin B. *Anal. Biochem.* **149**, 461 (1985).

Sigma catalog. pp. 294, 312, 351 (1989).

Sleath et al. Substrate specificity of the protease that processes human interleukin-1 $\beta$ . *J. Biol. Chem.* **285**, 14526 (1990).

Smith et al. Visualization of time-dependent inactivation of human tumor cathepsin B isoenzymes by a peptidyl fluoromethyl ketone using a fluorescent print technique. *Anticancer Res.* **8**, 525 (1988).

Stein. Catalysis by human leukocyte elastase 4. Role of secondary subsite interactions. *J. Am. Chem. Soc.* **107**, 5767 (1985).

Suggs et al. Use of synthetic oligonucleotides as hybridization probes: Isolation of cloned cDNA sequences for human  $\beta$ 2-microglobulin. *Proc. Natl. Acad. Sci. USA* **78**, 6613 (1981).

Tomasselli et al. Substrate analogue inhibition of active site titration of purified recombinant HIV-1 protease. *Biochemistry* **29**, 264 (1990).

Van Noorden et al. Cysteine proteinase activity in arthritic rat knee joints and the effects of a selective systemic inhibitor, Z-Phe-Ala-CH<sub>2</sub>F. *J. Rheumatol.* **15**, 10 (1988).

Woessner. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. *FASEB J.* **5**, 2145 (1991).

Young et al. Human interleukin 1 beta is not secreted from hamster fibroblasts constitutively from a transfected cDNA. *J. Cell. Biol.* **107**, 447 (1988).

Young. et al. Yeast RNA polymerase II genes: Isolation with antibody probes. *Science* **222**, 778 (1983).

The documents cited herein have been submitted in the prior applications.


Pursuant to 37 C.F.R. § 1.98(d), copies of documents being cited are not required to be submitted to the Patent and Trademark Office if (1) the documents have been previously

cited and/or submitted in a parent application, and (2) the parent application is clearly identified and relied upon for an earlier filing date. If the Examiner would like a copy of any of the art made of record in connection with the parents applications of this application, applicants stand ready to provide it.

Applicants request that these above-cited documents be (1) fully considered by the Examiner during the course of the examination of this application; and (2) printed on any patent that may issue from this application.

Applicants also request that a copy of Form PTO-1449, as considered and initialed by the Examiner, be returned to the undersigned with the next communication.

Respectfully submitted,



James F. Haley, Jr. (Reg. No. 27,794)

Attorney for Applicants

Min Wang (Reg. No. 51,303)

Kimberley A. Gavin (Reg. No. P-51,723)

Agents for Applicants

c/o Fish & Neave (Customer No. 1473)

1251 Avenue of the Americas


New York, New York 10020

Tel.: (212) 596-9000

Fax.: (212) 596-9090

I Hereby Certify that this  
Correspondence is being  
Deposited with the U.S.  
Postal Service as First  
Class Mail in an Envelope  
Addressed to:  
COMMISSIONER FOR  
PATENTS P.O. Box 2327  
ARLINGTON, VA 22202 on

July 23, 2002  
Lillian Garcia

  
Signature of Person Signing